Abilify lawsuits allege patients developed gambling addictions as a result of taking the atypical antipsychotic medication.
Product liability lawsuits filed against Bristol-Myers Squibb Co. and Otsuka Pharmaceutical Co. allege the manufacturers of Abilify failed to adequately warn doctors and patients of the potential risk of developing compulsive behaviors, such as gambling addictions, as a side affect of taking the drug. Abilify (aripiprazole ) is an atypical antipsychotic used to treat schizophrenia, bi-polar disorder and other psychiatric disorders in adults and children. The medication is marketed by Bristol-Myers Squibb and Otsuka Pharmaceutical Co. Among other things, Abilify impacts dopamine, a neurotransmitter that helps control the brain’s reward and pleasure centers. On January 20th, Courthouse News Service reported that an Abilify lawsuit had been filed in New Jersey’s Bergen County Superior Court on behalf of a man who claims to have developed a gambling addiction shortly after he began using Abilify in December 2010. The Plaintiff further claims that he was able to stop compulsively gambling after he ceased treatment with the drug in August 2013. According to Courthouse News Service, two additional Abilify lawsuits and compulsive gambling allegations were filed on January 13th in the U.S. District Court, Middle District of Florida. Court records further indicate that on January 12th, a fourth Abilify lawsuit was filed in the U.S. District Court, District of Minnesota, by a woman who allegedly incurred gambling losses in excess of $75,000 due to side effects associated with the medication. According to these complaints, dopaminergic reward pathways have frequently been implicated in the etiology of addictive behavior. Among other things, the Abilify lawsuits point out that scientific literature has identified dopamine as a potential cause of pathological gambling for years. Plaintiffs further note that in 2012, the European Medicines Agency required that defendants warn patients and the medical community in Europe that Abilify might be associated with pathological gambling. In November 2015, Health Canada warned that Abilify may be linked to certain compulsive behaviors, including a possible risk of pathological gambling . Yet the U.S. label for the medication fails to mention that pathological gambling has been reported in patients prescribed Abilify. Originally posted by Sandy Liebhard on PRLeap.com. Abilify Lawsuits – Ball & Bonholtzer Trial Attorney – Los Angeles